Free Trial
NYSE:MANE

Veradermics Q1 2026 Earnings Results & Report

Veradermics logo
$112.85 -3.41 (-2.93%)
Closing price 10/14/2026 03:59 PM Eastern
Extended Trading
$115.05 +2.21 (+1.95%)
As of 04:07 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Veradermics missed analyst earnings expectations in its Q1 2026 results, released May 12, 2026. The company reported EPS of -$1.32 versus the -$0.56 consensus estimate.

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
Before Market Opens
Conference Call
8:30 AM ET

Veradermics EPS Results

Actual EPS
-$1.32
Consensus EPS
-$0.56
Beat/Miss
Missed by -$0.76
One Year Ago EPS
N/A

Veradermics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Veradermics Q1 2026 Earnings FAQ

Veradermics (NYSE:MANE) reported earnings of -$1.32 per share for Q1 2026, missing the consensus estimate of -$0.56. The report was announced on Tuesday, May 12, 2026.

Veradermics Earnings Headlines

Veradermics: Buy Before The Catalysts
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.tc pixel
See More Veradermics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Veradermics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Veradermics and other key companies, straight to your email.

About Veradermics

Veradermics (NYSE:MANE), Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for dermatologic diseases. The company’s research and development efforts are aimed at addressing conditions that affect the skin, hair and nails, with an emphasis on treatments designed to improve patient outcomes and quality of life.

Veradermics is advancing a pipeline of investigational dermatology products across multiple disease areas. Its activities include the discovery, clinical development and potential commercialization of prescription therapies for conditions with unmet medical needs. As a development-stage company, its products remain subject to clinical testing and regulatory review before they can be broadly marketed.

The company is headquartered in the United States and serves the dermatology market through its pharmaceutical development programs. Additional details about its commercial product portfolio, international operations and leadership are limited based on publicly available information.

View Veradermics Profile